01Medicine developmentWhat it doesNeuShen develops experimental medicines for brain and nerve diseases, including schizophrenia, seizures, depression and Alzheimer’s agitation.Source-grounded · automated review · Explore ↗
02Who is involvedEvidence still neededOpen review status ↗
Misleading/incomplete. Document supports an undisclosed industry investor leading and participation by B Capital, Legend Capital, Matrix Partners China, ZhenFund, Shanghai State-owned Capital Investment, and existing investor Lilly Asia Ventures. Draft replaces two specifically named participants, i
03What happenedEvidence still neededOpen review status ↗
Supported as to event, round, currency, and amount: document says NeuShen Therapeutics announced the close of a Series B financing round exceeding USD 80 million. No valuation is stated, and the draft does not confuse amount with valuation. However the supplied document does not verify the target da
04Why it mattersThe funding supports broader clinical testing of NeuShen’s brain-disease drug programs across global study sites.Interpretation · Explore ↗